🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  2. Tislelizumab

    The First People's Hospital of Lianyungang

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  3. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    RECTAL NEOPLASMS

    phase 2 small molecule active

    1 trial

  4. Tislelizumab

    Hospital Authority, Hong Kong

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  5. Tislelizumab (BGB-A317)

    BEONE MEDICINES AUS PTY LTD

    MSI-H/dMMR Solid Tumors

    phase 2 small molecule active

    1 trial

  6. Toripalimab

    The First People's Hospital of Lianyungang

    Urinary Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  7. Total Neoadjuvant Treatment

    The First People's Hospital of Lianyungang

    Biliary Tract Neoplasms

    phase 2 small molecule active

    1 trial

  8. UC-MSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  9. UC-MSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cirrhosis Due to Hepatitis B

    phase 2 mab active

    1 trial

  10. US-guided laser ablation for refractory neoplasms

    The First People's Hospital of Lianyungang

    Refractory Neoplasms

    phase 2 other active

    1 trial

  11. Ublituximab

    TG THERAPEUTICS, INC.

    multiple sclerosis

    phase 2 small molecule active

    1 trial

  12. Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation

    Blackmores Limited

    Autism Spectrum Disorder

    phase 2 mab active

    1 trial

  13. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Myelodysplastic Neoplasms

    phase 2 small molecule active

    1 trial

  14. Vinflunine

    United Therapeutics Europe Ltd

    Locally-advanced or Metastatic Penile Neoplasms

    phase 2 small molecule completed

    1 trial

  15. Vir-3434, Vir-2218, Pegasys 180 micrograms solution for injection in pre-filled syringe

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  16. WJMSCs Vs. placebo

    The First People's Hospital of Lianyungang

    Ischemic Cardiomyopathy

    phase 2 mab active

    1 trial

  17. YERVOY 5 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion, DACARBAZINE

    Immunocore Ireland Limited

    Previously untreated advanced uveal melanoma (UM)

    phase 2 small molecule active

    1 trial

  18. YMSM

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior

    phase 2 other completed

    1 trial

  19. YTB323, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, TOCILIZUMAB

    Novartis Pharmaceuticals

    Non-active Progressive Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  20. Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Gilteritinib, ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung, Gilteritinib, Bendarabin 50 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Citarabina Hikma 1 g/10mL Soluzione Iniettabile

    Astellas Pharma GmbH

    FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  21. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  22. Zumsemetinib

    Aclaris Therapeutics

    Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  23. Zydena (Udenafil)

    Samsung Bioepis NL B.V.

    Vascular Dementia

    phase 2 small molecule active

    1 trial

  24. allogeneic human mesenchymal stem cells (hMSCs)

    United Therapeutics Europe Ltd

    Non-ischemic Dilated Cardiomyopathy

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources